Matrixx 30% Sales Growth Predicted For 2003 With Zicam Extensions
This article was originally published in The Tan Sheet
Matrixx Initiatives expects to achieve 30% sales growth in 2003 following a robust revenue gain of almost 50% in 2002, according to President & CEO Carl Johnson
You may also be interested in...
Matrixx Initiatives, formerly Gum Tech International, is introducing a novel delivery vehicle to the OTC cough/cold remedy market - Zicam Cold Remedy Swabs
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning